ARTICLE | Deals
Deals report: Roivant sets up Pulmovant to advance hypertension therapy
Plus: Candid joining two VC-backed start-ups to focus on autoimmune bispecifics, and updates from Eli Lilly, Haya, Genetic Leap and more
September 10, 2024 10:00 PM UTC
Roivant set up its newest subsidiary this week to house a hypertension program obtained via a licensing deal, while a large VC syndicate backed another start-up that will house two programs obtained via a pair of acquisitions.
On Tuesday, Roivant Sciences Ltd. (NASDAQ:ROIV) said it had acquired exclusive, worldwide rights to sGC activator mosliciguat from Bayer AG (Xetra:BAYN) and created wholly-owned subsidiary Pulmovant to advance the molecule’s development. The biotech paid $14 million up front; Bayer is eligible to receive $280 million in milestones, plus royalties...